NK cell membrane/MnO 2 hybrid nanoparticle-adjuvanted intranasal vaccines synergistically boost protective immunity against H1N1 influenza infection
Hanghang Cheng,Lingli Shen,Xiaoning Liu,Jian Huo,Shuqi Wang,Qun Niu,Haoxiang Yang,Yanan Wu,Xuannian Wang,Gaiping Zhang,Hua He
DOI: https://doi.org/10.1016/j.cej.2024.157381
IF: 15.1
2024-11-09
Chemical Engineering Journal
Abstract:Intranasal vaccines hold a huge promise for preventing influenza infection, however, their development is compromised due to mucosal barriers and limited systemic and mucosal immunity. Herein, a novel biomimetic nano-adjuvant based on NK cell membrane (M NK )/MnO 2 hybrid nanoparticles (NLipo Mn ) was developed for intranasal administration of H1N1 inactivated influenza vaccine (IIV). NK cell membrane, served as TLR4 agonist was fused with cationic liposomes encapsulating STING agonist MnO 2 NPs (Lipo Mn ) to yield NLipo Mn , which inherited versatile characteristics to prolong the nasal retention of IIV. Encouragingly, CCL20 secretion was enhanced by NLipo Mn -activated the TLR4/NF-κB pathway in mucosal endothelial cells, thereby promoting submucosal dendritic cells (DCs) recruitment for IIV uptake. Moreover, NLipo Mn -IIV synergistically harnessed TLR4 and STING signaling pathway to augment STING activation though NLipo Mn -activated the TLR4/NF-κB pathway, which demonstrated a superiority to elicit strong DCs maturation, CD8 + T cells activation, and high levels of antigen-specific IgG, antigen-specific IgA, cytokines secretion, resulting in a robust systemic and mucosal immune responses. Notably, intranasal immunization with NLipo Mn -IIV elicited an effective immune protection against homologous and heterologous H1N1 influenza virus infection. This study provides a promising adjuvant candidate to develop needle-free intranasal vaccines that are active against influenza and other respiratory viral infection.
engineering, chemical, environmental